(Q24197853)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24671923%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24671923%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

12 March 2020

main subject

meta-analysis

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24671923%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Sofia Dias

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24671923%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Christopher Cates

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24671923%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Kayleigh M Kew

1

0 references

Sofia Dias

2

0 references

Christopher J Cates

3

0 references

publication date

26 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24671923%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24671923%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24671923%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

CD010844

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24671923%20AND%20SRC:MED&resulttype=core&format=json

Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

A one-year trial of tiotropium Respimat plus usual therapy in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Tolerance to bronchodilating effects of salmeterol in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Withdrawal of treatment in the ISOLDE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Impact of preventing exacerbations on deterioration of health status in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The severity of airways obstruction as a determinant of treatment response in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Cardiovascular events in patients with COPD: TORCH study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Methods for therapeutic trials in COPD: lessons from the TORCH trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Adherence to inhaled therapy, mortality and hospital admission in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Beclomethasone/formoterol in the management of COPD: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Development and implementation of treadmill exercise testing protocols in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The effect of tiotropium on exacerbations and airflow in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Cardiovascular safety of salmeterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

ADRB2 polymorphisms and budesonide/formoterol responses in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Rapid fall in lung density following smoking cessation in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Premature discontinuation during the UPLIFT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Exacerbation frequency and course of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Safety of tiotropium therapy in chronic obstructive lung diseases (COPD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Bronchodilator responsiveness in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of an inhaled glucocorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Reported pneumonia in patients with COPD: findings from the INSPIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: phase III study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Smoking and lung function of Lung Health Study participants after 11 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Loss of bone density with inhaled triamcinolone in Lung Health Study II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Improvements with tiotropium in COPD patients with concomitant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Controlled trial of inhaled fluticasone propionate in moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Time course of response to oral and inhaled corticosteroids in non-asthmatic chronic airflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Does addition of inhaled steroid to combined bronchodilator therapy affect health status in patients with COPD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Checking consistency in mixed treatment comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Self-management education for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta-agonists or placebo for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Combination inhaled steroid and long-acting beta-agonist in addition to tiotropium versus tiotropium alone for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

The added effect of inhaled corticosteroids to tiotropium and long-acting beta 2 -agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Long-acting beta 2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta 2 -agonist alone for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Tiotropium versus placebo for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Long-acting beta2-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Pulmonary rehabilitation for chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Indacaterol: in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Safety of long-acting beta-agonists in stable COPD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Inhaled corticosteroids versus long acting beta-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Bayesian measures of model complexity and fit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Smoking cessation for chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Combination inhaled steroid and long-acting beta-agonist versus tiotropium for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Conceptual and Technical Challenges in Network Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

P255 ATTAIN: twice-daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

Tiotropium improves FEV1 in patients with COPD irrespective of smoking status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Tiotropium in COPD patients not previously receiving maintenance respiratory medications

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Indacaterol once-daily is equally effective dosed in the evening or morning in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT®)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Combined salmeterol and fluticasone for COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

[Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Tiotropium Respimat inhaler and the risk of death in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Importance of total serum IgE for improvement in airways hyperresponsiveness with inhaled corticosteroids in asthma and chronic obstructive pulmonary disease. The Dutch CNSLD Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5'-monophosphate in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Effect of High Dose Inhaled Steroid on Cells, Cytokines, and Proteases in Induced Sputum in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Health Status Deterioration in Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Premature discontinuation of patients: a potential bias in COPD clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Risk indexes for exacerbations and hospitalizations due to COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Inhaled budesonide therapy for patients with stable COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Effects of long-term treatment with corticosteroids in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch CNSLD Study Group. The Dutch Chronic Nonspecific Lung Disease Study Groups

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

The effect of high-dose inhaled beclomethasone dipropionate in patients with stable COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

EFFICACY OF TIOTROPIUM IN MEN AND WOMEN: 4-YEAR FOLLOW-UP IN THE UPLIFT TRIAL

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010844.PUB2

7 January 2021

10.1002/14651858.CD010844.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24671923%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017